- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06051565
Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients
Open-label, Single-dose Study of Polysaccharide Superparamagnetic Iron Oxide Injection for Contrast-enhanced Cardiovascular Magnetic Resonance Imaging in Patients With Type 2 Diabetes and Chronic Kidney Disease.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 101149
- Beijing Luhe Hospital, Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged ≥ 18 years, ≤ 80 years.
- Patients who have been diagnosed with chronic kidney disease (CKD) according to diagnostic criteria, meeting at least one CKD diagnostic criterion.
Patients with a confirmed history of atherosclerosis and/or chronic venous disease (including deep vein thrombosis, thrombotic venous inflammation, lower limb varicose veins, etc.) either in their medical history or diagnosed during hospital admission, and within the past year, at least one imaging examination has confirmed the presence of at least one of the following vascular abnormalities in at least one vascular bed:
- ≥50% vascular stenosis;
- Arterial aneurysm;
- Arterial dissection;
- Arteriovenous malformation;
- Arteriovenous fistula;
- Vascular developmental abnormalities;
- Varicose veins, etc. For details, please refer to the inclusion criteria section.
- Patients capable of self-care in daily life.
- Patients who voluntarily agree to participate in this study, sign an informed consent form, have a full understanding of the trial's content, procedures, and potential adverse reactions, and demonstrate good compliance.
- Patients who are unwilling to sign an informed consent form for the exploratory research can still be enrolled in the main study.
- Subjects who have no plans for pregnancy for at least 2 weeks before self-administration of the investigational drug and for at least 6 months after the last use of the investigational drug and voluntarily agree to adopt effective contraceptive measures.
Exclusion Criteria:
- Patients who have undergone stent implantation for vascular treatment in the target vascular bed.
- Patients who have had or currently have malignant tumors within the last 3 years.
- Serum ferritin > 1000 μg/L.
- Patients who are planned to undergo magnetic resonance imaging (MRI) examination for various reasons during the trial.
- Blood donation or significant blood loss (> 450 ml) within the two months before medication.
- Patients with a history of substance abuse involving psychotropic drugs and are unable to quit or have psychiatric disorders.
Patients with any severe and/or uncontrolled diseases, including:
- Outpatients diagnosed through medical history; inpatients diagnosed based on past medical history and current medical history indicating ≥ Grade 2 myocardial ischemia or myocardial infarction, ≥ Grade 2 congestive heart failure (New York Heart Association (NYHA) classification).
- Active or uncontrolled severe systemic infections (≥ Common Terminology Criteria for Adverse Events (CTCAE) 5.0 Grade 2).
- Infectious diseases such as cirrhosis, active hepatitis*, syphilis, human immunodeficiency virus (HIV), etc. *Reference for hepatitis B: hepatitis B surface antigen (HBsAg) positive and Hepatitis B Virus (HBV) DNA test value exceeds the upper limit of normal; Reference for hepatitis C: Hepatitis C Virus (HCV) antibody positive and HCV viral titer test value exceeds the upper limit of normal.
- History of immunodeficiency, acquired or congenital immunodeficiency diseases, or organ transplantation.
- Pregnancy or currently breastfeeding or planning to breastfeed during the study.
- Presence of metal objects in the body (dentures, contraceptive rings, metal implants, metal clips, etc.) and claustrophobia.
- Allergic reactions to the investigational drug, its metabolites, or excipients.
- Use of the investigational drug or participation in drug clinical trials within the two months before medication.
- Difficulty with or intolerance to MRI scans.
- Subjects who cannot or will not comply with the hospital management regulations.
- According to the investigator's judgment, patients with accompanying diseases that pose a serious risk to patient safety or may interfere with the completion of the study, or patients deemed unsuitable for inclusion for other reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Polysaccharide superparamagnetic iron oxide injection
Intravenous injected polysaccharide superparamagnetic iron oxide injection at 3 mg/kg dose
|
Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of vascular segments with lesions
Time Frame: 0 hour after administration
|
The number of vascular segments with lesions after administration
|
0 hour after administration
|
Lesion length
Time Frame: 0 hour after administration
|
Vascular lesion length
|
0 hour after administration
|
Degree of vascular stenosis
Time Frame: 0 hour after administration
|
Vascular stenosis degree
|
0 hour after administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse event rate
Time Frame: Baseline up to 24 hours after administration
|
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).
|
Baseline up to 24 hours after administration
|
Myocardium T1 values
Time Frame: 0 hour after administration
|
Changes from baseline in the longitudinal relaxation value of myocardial tissue.
|
0 hour after administration
|
Signal-to-noise ratio
Time Frame: 0 hour after administration
|
The strength of a signal relative to the background noise.
|
0 hour after administration
|
Contrast-to-noise ratio
Time Frame: 0 hour after administration
|
The visibility and distinguishability of structures or features of interest in an image in the presence of noise.
|
0 hour after administration
|
Serum iron
Time Frame: Baseline up to 24 hours after administration
|
Changes from baseline in the amount of circulating iron that is bound to transferrin and freely circulate in the blood.
|
Baseline up to 24 hours after administration
|
Serum ferritin
Time Frame: Baseline up to 30 days and 60 days after administration
|
Changes from baseline in the concentration of plasma (or serum) ferritin.
|
Baseline up to 30 days and 60 days after administration
|
Total iron-binding capacity
Time Frame: Baseline up to 30 days and 60 days after administration
|
Changes from baseline in the total amount of iron that can be bound by transferrin proteins in the blood.
|
Baseline up to 30 days and 60 days after administration
|
Serum transferrin saturation
Time Frame: Baseline up to 30 days and 60 days after administration
|
Changes from baseline in the value of serum iron divided by the total iron-binding.
|
Baseline up to 30 days and 60 days after administration
|
Image quality scores
Time Frame: 0 hour after administration
|
Vascular image quality was scored on a 4-point scale. 1 = Vessels not assessable due to poor image quality; 2 = Vessels visualized but only gross features (size/patency) confidently assessable; 3 = Vessels well defined and evaluable for structural pathology with high confidence; 4 = Excellent vessel definition with sharp borders such that fine details can be evaluated with high confidence.
|
0 hour after administration
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- DJTCSCYHT-I-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on Polysaccharide superparamagnetic iron oxide injection
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedMagnetic Resonance ImagingChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingChronic Kidney Diseases | Magnetic Resonance ImagingChina
-
The First Affiliated Hospital with Nanjing Medical...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completed
-
The First Affiliated Hospital with Nanjing Medical...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingChronic Kidney DiseasesChina
-
Vastra Gotaland RegionRecruitingBreast Cancer | Sentinel Lymph NodeSweden
-
Vastra Gotaland RegionActive, not recruitingBreast Cancer | Sentinel Lymph NodeSweden
-
Massachusetts General HospitalCompletedPancreatic CancerUnited States
-
The First Affiliated Hospital with Nanjing Medical...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Ruijin HospitalCompletedLung Neoplasm | Segmentectomy;Intersegmental PlaneChina
-
Baxter Healthcare CorporationQuotient SciencesCompletedBioequivalanceUnited States